Genmab AS (GMAB) - Total Assets
Based on the latest financial reports, Genmab AS (GMAB) holds total assets worth $12.84 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genmab AS - Total Assets Trend (2002–2025)
This chart illustrates how Genmab AS's total assets have evolved over time, based on quarterly financial data. Also see market cap of Genmab AS for the company's overall valuation and market capitalisation.
Genmab AS - Asset Composition Analysis
Current Asset Composition (December 2025)
Genmab AS's total assets of $12.84 Billion consist of 22.4% current assets and 77.6% non-current assets. Review Genmab AS (GMAB) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.3% |
| Accounts Receivable | $1.15 Billion | 9.0% |
| Inventory | $17.96 Million | 0.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.10 Billion | 70.9% |
| Goodwill | $354.19 Million | 2.8% |
Asset Composition Trend (2002–2025)
This chart illustrates how Genmab AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Genmab AS share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genmab AS's current assets represent 22.4% of total assets in 2025, a decrease from 89.6% in 2002.
- Cash Position: Cash and equivalents constituted 13.3% of total assets in 2025, down from 16.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 4.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 70.9% of total assets.
Genmab AS Competitors by Total Assets
Key competitors of Genmab AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Genmab AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.02 | 5.25 | 15.42 |
| Quick Ratio | 2.01 | 5.24 | 15.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.45 Billion | $22.55 Billion | $18.64 Billion |
Genmab AS - Advanced Valuation Insights
This section examines the relationship between Genmab AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.92 |
| Latest Market Cap to Assets Ratio | 1.26 |
| Asset Growth Rate (YoY) | -72.0% |
| Total Assets | $12.84 Billion |
| Market Capitalization | $16.23 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Genmab AS's assets above their book value (1.26x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Genmab AS's assets decreased by 72.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genmab AS (2002–2025)
The table below shows the annual total assets of Genmab AS from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $12.84 Billion | -71.96% |
| 2024-12-31 | $45.81 Billion | +29.82% |
| 2023-12-31 | $35.29 Billion | +17.17% |
| 2022-12-31 | $30.12 Billion | +22.30% |
| 2021-12-31 | $24.63 Billion | +16.48% |
| 2020-12-31 | $21.14 Billion | +39.61% |
| 2019-12-31 | $15.14 Billion | +78.99% |
| 2018-12-31 | $8.46 Billion | +28.14% |
| 2017-12-31 | $6.60 Billion | +26.05% |
| 2016-12-31 | $5.24 Billion | +34.23% |
| 2015-12-31 | $3.90 Billion | +36.13% |
| 2014-12-31 | $2.87 Billion | +65.56% |
| 2013-12-31 | $1.73 Billion | +2.28% |
| 2012-12-31 | $1.69 Billion | +8.21% |
| 2011-12-31 | $1.56 Billion | -36.96% |
| 2010-12-31 | $2.48 Billion | +11.71% |
| 2009-12-31 | $2.22 Billion | -31.83% |
| 2008-12-31 | $3.26 Billion | -17.68% |
| 2007-12-31 | $3.96 Billion | +119.37% |
| 2006-12-31 | $1.80 Billion | +31.68% |
| 2005-12-31 | $1.37 Billion | +7.75% |
| 2004-12-31 | $1.27 Billion | +7.78% |
| 2003-12-31 | $1.18 Billion | -25.46% |
| 2002-12-31 | $1.58 Billion | -- |
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more